Augmentation of Maxillary Horizontal And Vertical Bone Deficiency Using Mineralized Plasmatic Matrix

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03757195

Enrollment

Registered

2018-11-28

Start date

2018-11-15

Completion date

2020-10-25

Last updated

2018-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolar Ridge Abnormality of Maxilla

Keywords

Mineralized plasmatic matrix, sticky bone, plasma, autogeous fibrin glue

Brief summary

A new technique of grafting introduce called Mineralized plasmatic matrix. This technique can be used in grafting in anterior zone giving a good results and bone substitution occur using allograft or xenograft. The bone graft have a good consistency when it mixed with plasma give easy application, strength and stability of the graft. Also plasma rich with CGF (Cellular growth factors).

Detailed description

Patients suffering from anterior maxillary vertical and horizontal bone loss will be treated using a xeno-graft mixed with the same patient plasma that extracted from his own blood during the operation this graft will be stabilized by collagen membrane and surgical tags. Patients will be follow up for 6 months to measure amount of bone loss of the xeno-graft during this period post operative using C.B.C.T

Interventions

PROCEDUREAugmentation

combination product

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Age: from 20 to 40 years old * no history of previous grafting. * no History of previous implant placement * Medically Free e.g no debilitating diseases

Exclusion criteria

* Smoker patients. * Alcoholic patients * Pregnant. * Drug Abusers. * Hypertensive , Diabetic, having Problems or disease in Kidney and/or liver. * Thyroid Disease. * Problem in Vit.D absorption or in calcitonin hormone secretion. * History of blood transfusion or donating blood less than 4 months. * Patient under Corticosteroid therapy. * Neurologicaly unstable patients. * History of radiotherapy or chemo-therapy. * Patient undergo Spect C.T Scan less than 4 Months .

Design outcomes

Primary

Measure	Time frame	Description
amount of bone loss	change from baseline at 6 months	amount of bone loss after xenograft by CBCT

Countries

Egypt

Contacts

Primary ContactHany M Ahmed, B.D.S

hanyyusf4@gmail.com00201091971228

Backup ContactTarek I Abdallah, P.H.D

t_ghareeb@hotmail.com01282931864

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026